Hansa Biopharma AB 

Hansa Biopharma AB (publ) is a biopharmaceutical firm specializing in the creation of immunomodulatory treatments. Leveraging its unique enzyme technology platform, the company aims to facilitate organ transplants and tackle rare autoimmune conditions driven by immunoglobulin G (IgG), alongside developing solutions for gene therapy and cancer. Its flagship therapeutic candidate, Imlifidase, is an enzyme-based therapy designed to break down antibodies. This compound is currently undergoing Phase 3 clinical trials for use in patients receiving sensitized kidney transplants and those suffering from anti-GBM antibody disease. Additionally, Imlifidase is in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain Barré syndrome. The company's development pipeline also includes NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing), intended for repeated administration in autoimmune disorders, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement), a cancer immunotherapy. Furthermore, Hansa Biopharma has established a preclinical research collaboration with argenx BV to evaluate the combined therapeutic potential of their respective IgG-modulating technologies. Established in 2007, the company's base of operations is located in Lund, Sweden.